1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
REGULATORY
Truvada Clears Preliminary Review for PrEP Use, but Coverage Not Granted
A Japanese health ministry panel on February 5 gave the go-ahead to the filing of a public knowledge-based application for Gilead Sciences’ Truvada (emtricitabine + tenofovir disoproxil fumarate) for the prevention of HIV. The drug however failed to clinch health…
To read the full story
Related Article
- Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
- Takeda’s Fruzaqla in Line for Approval, Broader Labels for Truvada, Keytruda, Prevenar 20 Too
August 5, 2024
- Gilead Files Truvada for HIV Prevention in Japan
February 29, 2024
- Will Truvada Win Health Coverage as Japan’s First Drug for HIV Prevention?
February 5, 2024
- Council OKs Public-Knowledge Application for Truvada Use as PrEP for HIV
December 1, 2023
- HIV Groups Pin Hopes on MHLW’s Development Requests for Preventive Therapy
September 4, 2023
REGULATORY
- Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
- “Annual Reports” Allowed for CMC Changes with Minimal Impact: MHLW
February 17, 2025
- Japan to Approve EquMet Generics, More Copycats toward June Listing
February 17, 2025
- MHLW Lays Out Procedures for Transition to Trivalent Flu Shots
February 17, 2025
- J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27
February 14, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…